Profile data is unavailable for this security.
About the company
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
- Revenue in USD (TTM)1.83bn
- Net income in USD-440.24m
- Incorporated2003
- Employees2.10k
- LocationAlnylam Pharmaceuticals Inc675 W Kendall StCAMBRIDGE 02142-1168United StatesUSA
- Phone+1 (617) 551-8200
- Fax+1 (617) 551-8101
- Websitehttps://www.alnylam.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sarepta Therapeutics Inc | 1.24bn | -535.98m | 12.15bn | 1.31k | -- | 14.12 | -- | 9.77 | -6.15 | -6.15 | 13.46 | 9.17 | 0.389 | 0.5708 | 4.04 | 946,222.30 | -16.77 | -21.63 | -20.94 | -25.75 | 87.91 | 86.65 | -43.11 | -77.05 | 3.45 | -- | 0.5903 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
Medpace Holdings Inc | 1.89bn | 282.62m | 12.43bn | 5.90k | 45.54 | 22.18 | 40.21 | 6.59 | 8.87 | 8.87 | 59.24 | 18.22 | 1.25 | -- | 6.84 | 319,634.30 | 18.80 | 13.94 | 44.16 | 23.18 | 27.81 | 28.84 | 15.00 | 15.23 | -- | 690.22 | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
Exact Sciences Corp | 2.50bn | -204.15m | 12.54bn | 6.50k | -- | 3.98 | 5,020.64 | 5.02 | -1.14 | -1.14 | 13.81 | 17.34 | 0.3937 | 5.32 | 13.82 | 384,579.40 | -3.22 | -9.71 | -3.47 | -10.60 | 73.83 | 74.10 | -8.17 | -28.21 | 2.07 | -- | 0.4311 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
Incyte Corp | 3.70bn | 597.60m | 12.79bn | 2.52k | 21.55 | 2.46 | 18.80 | 3.46 | 2.64 | 2.64 | 16.36 | 23.14 | 0.5855 | 4.43 | 5.32 | 1,464,203.00 | 9.47 | 9.07 | 11.69 | 11.02 | 93.71 | 94.97 | 16.17 | 13.68 | 3.69 | -- | 0.0062 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
Neurocrine Biosciences, Inc. | 1.89bn | 249.70m | 13.72bn | 1.40k | 56.72 | 6.10 | 50.64 | 7.27 | 2.43 | 2.43 | 18.84 | 22.61 | 0.6716 | 1.08 | 4.78 | 1,347,929.00 | 8.89 | 9.77 | 11.28 | 12.19 | 97.90 | 98.51 | 13.23 | 14.79 | 2.40 | -- | 0.0708 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
Charles River Lbrtrs ntrntl Inc | 4.13bn | 474.62m | 13.91bn | 20.00k | 29.36 | 3.87 | 17.51 | 3.37 | 9.23 | 9.23 | 80.25 | 70.06 | 0.5228 | 8.19 | 5.39 | 206,470.50 | 6.08 | 6.46 | 7.09 | 7.62 | 36.89 | 36.99 | 11.63 | 11.58 | 1.16 | 4.97 | 0.4203 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
Viatris Inc | 15.43bn | 54.70m | 14.18bn | 38.00k | 282.07 | 0.7005 | 5.07 | 0.9192 | 0.0423 | 0.0423 | 12.81 | 17.05 | 0.3158 | 2.49 | 5.09 | 405,971.10 | 0.112 | 0.0887 | 0.1315 | 0.1061 | 43.64 | 40.29 | 0.3546 | 0.2891 | 1.22 | 2.79 | 0.4696 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
Biomarin Pharmaceutical Inc | 2.42bn | 167.65m | 16.48bn | 3.40k | 99.48 | 3.33 | 60.58 | 6.81 | 0.878 | 0.878 | 12.58 | 26.25 | 0.3661 | 0.5145 | 4.42 | 711,327.90 | 2.54 | 0.7773 | 2.93 | 0.8825 | 78.72 | 76.30 | 6.93 | 2.24 | 1.57 | -- | 0.18 | 0.00 | 15.42 | 10.16 | 18.43 | -- | -5.74 | -- |
Alnylam Pharmaceuticals, Inc. | 1.83bn | -440.24m | 18.82bn | 2.10k | -- | -- | -- | 10.30 | -3.59 | -3.59 | 14.46 | -1.75 | 0.4957 | 2.85 | 8.43 | 870,615.30 | -11.94 | -26.56 | -15.61 | -32.77 | 83.02 | 83.66 | -24.08 | -94.26 | 2.99 | -2.11 | 1.28 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
Holder | Shares | % Held |
---|---|---|
Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 16.17m | 12.84% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 11.65m | 9.25% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 9.84m | 7.81% |
Wellington Management Co. LLPas of 31 Dec 2023 | 7.21m | 5.73% |
Baillie Gifford & Co.as of 31 Dec 2023 | 6.97m | 5.53% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 6.05m | 4.80% |
Dodge & Coxas of 31 Dec 2023 | 3.67m | 2.92% |
Capital Research & Management Co. (International Investors)as of 31 Dec 2023 | 3.59m | 2.85% |
T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 3.43m | 2.72% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 3.39m | 2.69% |